首页> 外文期刊>Journal of population therapeutics and clinical pharmacology >The Study of Drugs for Rare Disorders: Harnessing Research Contributions by Canadian Academic Institutions
【24h】

The Study of Drugs for Rare Disorders: Harnessing Research Contributions by Canadian Academic Institutions

机译:罕见疾病药物的研究:利用加拿大学术机构的研究成果

获取原文
           

摘要

Genetic research in Canadian universities is in the midst of a revolution brought about by new technologies that have led in the past five years to astonishing increases in DNA sequencing capacity at a reduction of per-nucleotide cost of many thousandfold. 1 These and other developments are producing an improved understanding of the genetic landscape of the cell, 2 and increased insight into the interplay of genetic and environmental factors. These are often manifested in epigenetic changes, which can now also be monitored using high-throughput techniques, 3 and which regulate physiologic and pharmacologic processes. Continued progress in the academic setting is critical if Canada is to meet its share of research responsibilities and to use this improved scientific understanding to support optimal patient care.
机译:加拿大大学的基因研究正处于新技术带来的革命之中,在过去五年中,新技术导致DNA测序能力的惊人提高,而每核苷酸的成本却降低了数千倍。 1这些和其他进展使人们对细胞的遗传景观有了更好的了解,2并增加了对遗传和环境因素相互作用的了解。这些通常表现在表观遗传变化中,现在也可以使用高通量技术3对其进行监测,并调节生理和药理过程。如果加拿大要履行自己的研究职责,并利用这种不断发展的科学知识来支持最佳的患者护理,那么学术环境中的持续进步至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号